The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Biochemical survival and morbidity of high-intensity focused ultrasound (HIFU) as a primary monotherapy for low-risk localized prostate cancer: Outcomes from the @-registry following the ENLIGHT trial inclusion criteria.
Cary N. Robertson
Consultant or Advisory Role - EDAP-TMS
Expert Testimony - EDAP-TMS (U)
Other Remuneration - EDAP-TMS
John Francis Ward
Consultant or Advisory Role - EDAP-TMS
Sebastien Crouzet
Consultant or Advisory Role - EDAP-TMS
Stephen CW Brown
Consultant or Advisory Role - EDAP-TMS
Victor Berge
Consultant or Advisory Role - EDAP-TMS
Christian G Chaussy
Consultant or Advisory Role - EDAP-TMS
Roman Ganzer
Consultant or Advisory Role - EDAP-TMS
Antonello Paulsau
Consultant or Advisory Role - EDAP-TMS
Albert Gelet
Consultant or Advisory Role - EDAP-TMS
Stefan Thueroff
Consultant or Advisory Role - EDAP-TMS
Andreas Blana
Consultant or Advisory Role - EDAP-TMS